This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Binaschi, M. Articles by Capranico, G. Search for Related Content PubMed PubMed Citation Articles by Binaschi, M. Articles by Capranico, G.

In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines¹

Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan [M. B., R. F., E. B., G.C.], and G. Moruzzi Department of Biochemistry, Bologna University, 40126 Bologna [G. C.], Italy

Anthracyclines exert antitumor activity by stimulating site-selective DNA cleavage by topoisomerase II (top2). DNA cleavage sites stimulated by two anthracycline analogues, dh-EPI and da-IDA, were investigated at the histone gene cluster of cultured Drosophila Kc cells. The two agents stimulated analogue-specific patterns of double-stranded DNA cleavage in Kc cell chromatin. Analyses of 47 base sequences of dh-EPI sites showed that the analogue largely followed the in vitro selectivity rule, the requirement of ^5'TA at 3' ends of cleaved strands. da-IDA was more selective than dh-EPI, and thus fewer sites could be collected. Nevertheless, base sequences were consistent with its in vitro base preferences. DNA cleavage was then studied in vitro with Drosophila and human top2 isoforms. The tested drugs stimulated distinct in vitro patterns that corresponded to the in vivo patterns. Human top2 promoted cleavage patterns that were much more similar to those of Drosophila top2 (both in vitro and in vivo) than human top2ß. Moreover, da-IDA showed a marked site-dependent preference for human top2ß. Thus, DNA site selection in vivo is different for the test anthracyclines, and together with a degree of ß-form specificity, may affect drug activity in human cells.

This article has been cited by other articles:

				B.-G. Ju, V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass, and M. G. Rosenfeld A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science, June 23, 2006; 312(5781): 1798 - 1802. [Abstract] [Full Text] [PDF]

				K. Lemke, M. Wojciechowski, W. Laine, C. Bailly, P. Colson, M. Baginski, A. K. Larsen, and A. Skladanowski Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities Nucleic Acids Res., October 27, 2005; 33(18): 6034 - 6047. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]